Topics

Herzuma gains Japanese approval for three-week cycle method

06:29 EDT 13 Sep 2019 | Generics and Biosimilars Initiative

South Korean biotechnology company Celltrion announced at the end of August 2019 that Japan's Ministry of Health, Labour and Welfare (MHLW) had approved a three-week cycle method for its trastuzumab biosimilar, Herzuma (CT P6), in the treatment of breast cancer.

Original Article: Herzuma gains Japanese approval for three-week cycle method

NEXT ARTICLE

More From BioPortfolio on "Herzuma gains Japanese approval for three-week cycle method"

Quick Search

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...